Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
Authors
Keywords
Dabigatran, Rivaroxaban, Apixaban, Dabigatran Etexilate, Direct Oral Anticoagulant
Journal
CLINICAL PHARMACOKINETICS
Volume 53, Issue 1, Pages 1-16
Publisher
Springer Nature
Online
2013-09-02
DOI
10.1007/s40262-013-0100-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Laboratory testing of rivaroxaban in routine clinical practice: When, how, and which assays
- (2013) Edelgard Lindhoff-Last et al. ANNALS OF MEDICINE
- Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor
- (2013) Dagmar Kubitza et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects
- (2013) Wolfgang Mueck et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- The effect of food on the absorption and pharmacokinetics of rivaroxaban
- (2013) Jan Stampfuss et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban-An Oral, Direct Factor Xa Inhibitor
- (2013) Dagmar Kubitza et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Absence of Clinically Relevant Interactions between Rivaroxaban - an Oral, Direct Factor Xa Inhibitor - and Digoxin or Atorvastatin in Healthy Subjects
- (2013) D Kubitza et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- Which test to use to measure the anticoagulant effect of rivaroxaban: the anti-factor Xa assay
- (2013) M. M. Samama JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients
- (2013) Alexander T. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran
- (2012) Joachim Stangier et al. BLOOD COAGULATION & FIBRINOLYSIS
- Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes
- (2012) Xu Steven Xu et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin
- (2012) Sebastian Härtter et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Oral Anticoagulant Therapy
- (2012) Walter Ageno et al. CHEST
- Model-based Dose Selection for Phase III Rivaroxaban Study in Japanese Patients with Non-valvular Atrial Fibrillation
- (2012) Takahiko Tanigawa et al. Drug Metabolism and Pharmacokinetics
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
- (2012) NEW ENGLAND JOURNAL OF MEDICINE
- Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin
- (2012) Gabriele Rohde et al. THROMBOSIS AND HAEMOSTASIS
- Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate
- (2011) Elise S. Eerenberg et al. CIRCULATION
- Rivaroxaban
- (2011) Wolfgang Mueck et al. CLINICAL PHARMACOKINETICS
- Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment
- (2011) K. A. A. Fox et al. EUROPEAN HEART JOURNAL
- Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Rivaroxaban
- (2011) Kenneth Todd Moore et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban
- (2011) M. J. Gnoth et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
- (2011) Manesh R. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
- (2011) Jessica L. Mega et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of the Efficacy and Safety of Rivaroxaban Using a Computer Model for Blood Coagulation
- (2011) Rolf Burghaus et al. PLoS One
- Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls
- (2011) Genevieve Contant et al. THROMBOSIS AND HAEMOSTASIS
- Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor
- (2010) Dagmar Kubitza et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure
- (2010) Mihai Gheorghiade et al. JOURNAL OF HEART AND LUNG TRANSPLANTATION
- The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor
- (2010) Elisabeth Perzborn et al. NATURE REVIEWS DRUG DISCOVERY
- Oral Rivaroxaban for Symptomatic Venous Thromboembolism
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Assays for Measuring Rivaroxaban: Their Suitability and Limitations
- (2010) Edelgard Lindhoff-Last et al. THERAPEUTIC DRUG MONITORING
- Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay
- (2010) Zhaoqing Wang et al. THROMBOSIS AND HAEMOSTASIS
- Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor
- (2010) Jean-Luc Martinoli et al. THROMBOSIS AND HAEMOSTASIS
- The mechanism of action of rivaroxaban – an oral, direct Factor Xa inhibitor – compared with other anticoagulants
- (2010) Meyer Michel Samama THROMBOSIS RESEARCH
- Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects
- (2009) Xia Zhao et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery
- (2009) Wolfgang Mueck et al. CLINICAL PHARMACOKINETICS
- Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and Humans
- (2009) C. Weinz et al. DRUG METABOLISM AND DISPOSITION
- Randomized, Double-Blind, Crossover Study to Investigate the Effect of Rivaroxaban on QT-Interval Prolongation
- (2009) Dagmar Kubitza et al. DRUG SAFETY
- Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial
- (2009) JL Mega et al. LANCET
- Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial
- (2009) Alexander GG Turpie et al. LANCET
- Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban – an oral, direct factor Xa inhibitor – in elderly Chinese subjects
- (2009) J. Jiang et al. THROMBOSIS AND HAEMOSTASIS
- Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects
- (2008) Dagmar Kubitza et al. CURRENT MEDICAL RESEARCH AND OPINION
- Determination of rivaroxaban – a novel, oral, direct Factor Xa inhibitor – in human plasma by high-performance liquid chromatography–tandem mass spectrometry
- (2008) G. Rohde JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
- (2008) Ajay K Kakkar et al. LANCET
- Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
- (2008) Bengt I. Eriksson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty
- (2008) Michael R. Lassen et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started